A company that pays out close to half its earnings as dividends and retains the other half of earnings has ample room to grow its business and pay out more dividends in the future. Keith Speights … Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.It's not uncommon for traders to buy and sell biotech stocks in attempts to make quick profits. Check. Axsome Therapeutics, Inc. Common Stock (AXSM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Get the latest Axsome Therapeutics, Inc. (AXSM) stock news and headlines to help you in your trading and investing decisions. It's better to instead focus on Axsome's prospects for its pipeline candidates. Real time Axsome Therapeutics (AXSM) stock price quote, stock graph, news & analysis.
Are they still buys today?One big biotech and two small biotechs especially stand out as attractive picks.AXSM earnings call for the period ending September 30, 2019.One of the best investments of 2019 fell on hard times in the first six months of 2020, but it's not as bad as it seems.Demand for Alzheimer's medication is expected to grow as the population of older adults rises.AXSM earnings call for the period ending December 31, 2019.Positive results from two pivotal trials helped this stock bounce back from a beatdown in March.An important drug candidate failed to meet its primary endpoint in a clinical trial. The drugmaker intends to submit for FDA approval of AXS-05 in treating MDD in the latter part of this year. Axsome Therapeutics stock price target raised to $140 from $100 at SunTrust RH. But has too much anticipated success already been priced into its shares?The biotech reported positive news from a late-stage clinical study targeting Alzheimer's disease agitation.Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Our pipeline includes four differentiated clinical-stage CNS assets targeting significant and growing markets.
Returns as of 07/30/2020. Cash from public stock offering? Dec. 31, 2019 at 8:01 a.m.
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder. Those prospects continue to look very good.There are three primary things for investors to watch with Axsome in the coming months. Some of our product candidates combine multiple mechanisms of action to produce novel medicines that address deficiencies of current approaches. These actions create pressure that can cause stocks to fall.But long-term investors shouldn't pay much attention to the noise created by these kinds of swings. ET by Tomi Kilgore.